EFFECTIVENESS OF RABEPRAZOLE FOR THE TREATMENT OF ACID-RELATED DISEASES
https://doi.org/10.21518/2079-701X-2017-5-116-118
Abstract
The analysis of modern data about the effectiveness of rabeprazole in the treatment of acid-related diseases is performed. The European Consensus Maastricht 5 recommends a preferred use of rabeprazole in the schemes of eradication of Helicobacter pylori. Clinical studies confirmed the high efficiency of rabeprazole for the treatment of GERD, and prevention of NSAID-induced gastropathy. Modern and effective generic of rabeprazole is Rabiet.
About the Authors
V. V. Tsukanov
Federal Research Center of Krasnoyarsk Scientific Center», Siberian branch of the Russian Academy of Sciences, separated subdivision «Scientific-research Institute of medical problems of the North»
Russian Federation
Russian Federation
MD,Prof.
E. V. Kasparov
Federal Research Center of Krasnoyarsk Scientific Center», Siberian branch of the Russian Academy of Sciences, separated subdivision «Scientific-research Institute of medical problems of the North»
Russian Federation
Russian Federation
MD,Prof.
A. V. Vasyutin
Federal Research Center of Krasnoyarsk Scientific Center», Siberian branch of the Russian Academy of Sciences, separated subdivision «Scientific-research Institute of medical problems of the North»
Russian Federation
Russian Federation
PhD in medicine
Y. L. Tonkikh
Federal Research Center of Krasnoyarsk Scientific Center», Siberian branch of the Russian Academy of Sciences, separated subdivision «Scientific-research Institute of medical problems of the North»
Russian Federation
Russian Federation
PhD in medicine
O. V. Peretyatko
Federal Research Center of Krasnoyarsk Scientific Center», Siberian branch of the Russian Academy of Sciences, separated subdivision «Scientific-research Institute of medical problems of the North»
Russian Federation
Russian Federation
References
1. Агеева Е.С., Штыгашева О.В., Рязанцева Н.В., Цуканов В.В. Молекулярно-генетические факторы, влияющие на исход инфицирования Helicobacter pylori у жителей Республики Хакасия. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии, 2010, 20(4): 16-21.
2. Meyer UA. Metabolic interactions of the protonpump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol, 1996, 8(Suppl 1): S21-S25.
3. Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter, 2008, 13(6): 532-541.
4. Kuo CH, Lu CY, Shih HY, Liu CJ, Wu MC, Hu HM et al. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol, 2014, 20(43): 16029-16036.
5. McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther, 2012, 36(5): 414-425.
6. Fujioka T, Aoyama N, Sakai K, Miwa Y, Kudo M, Kawashima J et al. A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in Japan. J Gastroenterol, 2012, 47(3): 276-283.
7. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT et al. Management of Helicobacter pylori infectionthe Maastricht V/Florence Consensus Report. Gut, 2017, 66(1): 6-30.
8. Буторин Н.Н., Бичурина Т.Б., Цуканов В.В., Каспаров Э.В., Куклин Д.В., Тимошенко В.О. и др. Распространенность и клинические аспекты пищевода Барретта у населения Восточной Сибири. Терапевт. архив, 2013, 85(1): 62-65.
9. Цуканов В.В., Онучина Е.В., Васютин А.В., Буторин Н.Н., Амельчугова О.С. Клинические аспекты гастроэзофагальной рефлюксной болезни у лиц пожилого возраста: результаты 5-летнего проспективного исследования. Терапевт. архив, 2014, 86(2): 23-26.
10. Цуканов В.В., Каспаров Э.В., Онучина Е.В., Васютин А.В., Буторин Н.Н., Амельчугова О.С., Тонких Ю.Л. Частота и клинические аспекты внепищеводных синдромов у пациентов с гастроэзофагеальной рефлюксной болезнью пожилого возраста. Терапевт. архив, 2016, 88(2): 28-32.
11. Scarpellini E, Ang D, Pauwels A, De Santis A, Vanuytsel T, Tack J. Management of refractory typical GERD symptoms. Nat Rev Gastroenterol Hepatol, 2016, 13(5): 281-294.
12. Fass R, Gasiorowska A. Refractory GERD: what is it? Curr Gastroenterol Rep, 2008, 10(3): 252-257.
13. Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T, Brockmöller J. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol, 2009, 65(1): 19-31.
14. Kinoshita Y, Ashida K, Hongo M et al. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. Aliment Pharmacol Ther, 2011, 33(2): 213-224.
15. Cutler A, Robinson M, Murthy A, Delemos B. Rabeprazole 20 mg for erosive esophagitis-associated symptoms in a large, community-based study: additional results. Dig Dis Sci, 2010, 55(2): 338-345.
16. Caos A, Breiter J, Perdomo C, Barth J. Long-term prevention of erosive or ulcerative gastrooesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. Aliment Pharmacol Ther, 2005, 22(3): 193-202.
17. Евсютина Ю.В., Трухманов А.С. Недостаточный ответ на терапию ингибиторами протонного насоса: причины и тактика ведения пациентов. Терапевт. архив, 2015, 87(2): 85-89.
18. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н., Ивашкин В.Т., Чичасова Н.В., Алексеева Л.И. и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология, 2015, (1): 4-23.
19. Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf, 2014, 37(4): 201-211.
20. Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med, 2005, 352(3): 238-244.
21. Wang ZY, Chen M, Zhu LL, Yu LS, Zeng S, Xiang MX, Zhou Q. Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Ther Clin Risk Manag, 2015, 11: 449-467.
22. Marelli S, Pace F. Rabeprazole for the treatment of acid-related disorders. Expert Rev Gastroenterol Hepatol, 2012, 6(4): 423-435.
Review
For citations:
Tsukanov VV, Kasparov EV, Vasyutin AV, Tonkikh YL, Peretyatko OV. EFFECTIVENESS OF RABEPRAZOLE FOR THE TREATMENT OF ACID-RELATED DISEASES. Meditsinskiy sovet = Medical Council. 2017;(5):116-118. (In Russ.) https://doi.org/10.21518/2079-701X-2017-5-116-118
Views:
6032
Email this article 